Key Resources


ASGE Guidelines

ASGE evidence-based guidelines provide clinicians with recommendations for the evaluation, diagnosis, and management of patients undergoing endoscopic procedures of the digestive tract. Guidelines are not a substitute for physicians’ opinion on individual patients. Final decision on an intervention should always be based on local expertise and patient preferences.

All recommendations follow a rigorous process based on a systematic review of medical literature as outlined by the National Academy of Medicine (formerly Institute of Medicine) standards for guideline development.

Whenever possible, guidelines are based on the GRADE (Grading of Recommendation Assessment, Development and Evaluation) methodology.

Panels consist of content experts, stakeholders from other specialties, patient representatives, and members of the ASGE Standards of Practice (SOP) Committee.

Each recommendation is based on consideration of the best medical literature, the balance between risks and benefits, cost-effectiveness, patients’ values, and equity.

Panel members provide ongoing conflict of interest (COI) disclosures, including intellectual conflicts of interest, throughout the development and publication of all guidelines in accordance with the ASGE Policy for Managing Declared Conflicts of Interests.

ASGE strives to provide clinically relevant and practical recommendations, which can help standardize patient care and improve outcomes.

If you have any questions or suggestions, please contact Customer Support at Info@asge.org.

The following information is intended only to provide general information and not as a definitive basis for diagnosis or treatment in any particular case. It is very important that you consult your doctor about your specific condition.

Newly Published

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
GRADE Guidelines

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Upper GI

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Lower GI

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Biliary and Pancreatic Endoscopy

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Adverse Events

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Privileging and Credentialing

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
GI Endoscopy Unit Operations

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Screening and Surveillance in Premalignant Conditions

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Procedural Management in Endoscopy

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Miscellaneous

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE
Guidelines in Spanish

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE

In Progress Guidelines

ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility

Estimated 2021

ASGE Guideline on the Role of Endoscopic Submucosal Dissection in the Management of Esophageal and Gastric Mucosal Neoplasia

Estimated 2021

Adverse events associated with endoscopic ultrasound (EUS) and EUS-guided procedures

Estimated 2021

Quality in Endoscopy

Quality documents define the indicators of high-quality endoscopy and how to measure it. ASGE quality indicators are based on a rigorous review process which results in valid metrics for evaluating GI endoscopic procedures. 

Quality in Endoscopy

ASGE guideline on the management of achalasia

Mar 3, 2020, 11:01 AM
Achalasia is a primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body. The criterion standard for diagnosing achalasia is highresolution esophageal manometry showing incomplete relaxation of the EGJ coupled with the absence of organized peristalsis. Three achalasia subtypes have been defined based on high-resolution manometry findings in the esophageal body. Treatment of patients with achalasia has evolved in recent years with the introduction of peroral endoscopic myotomy. Other treatment options include botulinum toxin injection, pneumatic dilation, and Heller myotomy. This American Society for Gastrointestinal Endoscopy Standards of Practice Guideline provides evidence-based recommendations for the treatment of achalasia, based on an updated assessment of the individual and comparative effectiveness, adverse effects, and cost of the 4 aforementioned achalasia therapies. (Gastrointest Endosc 2020;91:213-27.)
Mouen A. Khashab, MD,1,* Marcelo F. Vela, MD,2,* Nirav Thosani, MD,3,* Deepak Agrawal, MD, MPH, MBA,4 James L. Buxbaum, MS, FASGE,5 Syed M. Abbas Fehmi, MD, MSc, FASGE,6 Douglas S. Fishman, MD, FAAP, FASGE,7 Suryakanth R. Gurudu, MD, FASGE,2 Laith H. Jamil, MD, FASGE,8 Terry L. Jue, MD, FASGE,9 Bijun Sai Kannadath, MBBS, MS,3 Joanna K. Law, MD,10 Jeffrey K. Lee, MD, MAS,11 Mariam Naveed, MD,12 Bashar J. Qumseya, MD, MPH,13 Mandeep S. Sawhney, MD, MS, FASGE,14 Julie Yang, MD, FASGE,15 Sachin Wani, MD, ASGE Standards of Practice Committee Chair16
Title : ASGE guideline on the management of achalasia
Doi org link : https://doi.org/10.1016/j.gie.2019.04.231
Volume : Gastrointest Endosc February 2020, Volume 91, Issue 2, Pages 213-227.e6
URL :
Select a choice : Keep
Content created : Mar 3, 2020, 11:00 AM
File size :
Number :
ExternalPK :
Categories :
Tags :
ASGE guideline on the management of achalasia 2020 February GIE

Technology Assessments

Technology evaluations provide a review of existing, new, or emerging endoscopic technologies that have an impact on the practice of GI endoscopy. Evaluations are based on a literature review and a search of the MAUDE (U.S. Food and Drug Administration Center for Devices and Radiological Health) database to identify the reported adverse events of a given technology. When financial guidance is indicated, the most recent coding data and list prices at the time of publication are provided.

Technology Assessments
80_logo